REGN
Regeneron·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About REGN
Regeneron Pharmaceuticals, Inc.
A company that developing drugs to treat eye diseases, inflammatory diseases and cancer
777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
Production and sales of pharmaceutical products
Regeneron Pharmaceuticals, Inc. was incorporated in New York State in 1988. The company is a fully integrated biotechnology company that invents, develops, manufactures and commercializes medicines for people with serious diseases. Its core business strategy is built on a strong foundation of scientific research and proprietary technology, advancing a diverse portfolio of products and product candidates across multiple therapeutic areas.
Company Financials
EPS
REGN has released its 2025 Q4 earnings. EPS was reported at 11.44, versus the expected 10.52, beating expectations. The chart below visualizes how REGN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
REGN has released its 2025 Q4 earnings report, with revenue of 3.88B, reflecting a YoY change of 2.51%, and net profit of 844.60M, showing a YoY change of -7.97%. The Sankey diagram below clearly presents REGN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
